NATALIE VALLE: Open Payments
NPI 1871092064 · FULLERTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$461 in 13 payments from 8 companies in 2025. Trend: 2023 $302 · 2024 $609 · 2025 $461
Food & beverage: $461
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $159 |
| ABBVIE INC. | 3 | $78 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $60 |
| Lilly USA, LLC | 2 | $43 |
| Merck Sharp & Dohme LLC | 2 | $38 |
| Genentech USA, Inc. | 1 | $28 |
| Karyopharm Therapeutics Inc. | 1 | $28 |
| SERVIER PHARMACEUTICALS LLC | 1 | $26 |
Products named: EPKINLY, VERZENIO, KEYTRUDA, IMFINZI, Itovebi, XPOVIO, Voranigo.
Industry payments across CA — which companies pay providers there.
